ADAM2

Overview

ADAM2 (A Disintegrin And Metalloproteinase 2) encodes a member of the ADAM family of membrane-anchored metalloproteinases. In the cancer genomics corpus, ADAM2 has been identified as a somatically mutated gene in the axon-guidance pathway in adenoid cystic carcinoma (ACYC), a rare salivary-gland malignancy known for perineural invasion — a phenotype mechanistically linked to disrupted axon-guidance signalling.

Alterations observed in the corpus

• Single-tumour somatic mutation in the axon-guidance pathway identified in adenoid cystic carcinoma (ACYC); the axon-guidance pathway was disrupted in 56% of tumours in the cohort PMID:26862087

Cancer types (linked)

• ACYC (Adenoid Cystic Carcinoma): ADAM2 was among a set of axon-guidance genes somatically mutated in ACYC, a cancer whose hallmark perineural invasion phenotype may be mechanistically linked to this pathway disruption PMID:26862087

Co-occurrence and mutual exclusivity

• Co-mutated with other axon-guidance pathway genes (ADAMTS5, ADAMTS13, PLXNA1, SLIT1, SRGAP2, SRGAP3, SEMA3G) in ACYC PMID:26862087

Therapeutic relevance

• No direct therapeutic targeting established. Rho-pathway and axon-guidance pathway inhibition are proposed as candidate therapeutic strategies in ACYC PMID:26862087

Open questions

• The functional consequence of ADAM2 somatic mutation in ACYC perineural invasion has not been established; the association is hypothesis-generating PMID:26862087

Sources

• PMID:26862087

This page was processed by crosslinker on 2026-05-14.